PMIHIGH SIGNALFINANCIAL10-Q

The company completed a significant debt restructuring that dramatically reduced total liabilities by 88% while raising $17.4 million in equity financing, though operating losses expanded substantially.

This appears to be a major financial restructuring event where the company converted or eliminated approximately $40 million in liabilities, likely through debt-to-equity conversion or forgiveness, while simultaneously raising fresh equity capital. The substantial reduction in the liability burden should improve the company's financial flexibility, though the meaningful expansion in operating losses indicates ongoing operational challenges that required this financial intervention.

Comparing 2025-11-14 vs 2025-09-12View on EDGAR →
FINANCIAL ANALYSIS

The company underwent a dramatic balance sheet transformation, with current liabilities plummeting from $45.6M to $5.4M and total liabilities falling similarly, while current assets grew modestly to $11.6M. Operating performance deteriorated substantially with net losses expanding meaningfully year-over-year, accompanied by higher R&D spending. The financing activity mentioned in the language changes—$17.4 million in equity proceeds and $3.7 million in net debt—suggests this was a comprehensive recapitalization effort to address the company's historically unprofitable operations.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-88.2%
$45.6M→$5.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-87.9%
$45.9M→$5.6M

Liabilities reduced 87.9% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
-55.1%
-$6.7M→-$10.4M

Net income declined 55.1% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+28%
$743K→$951K

R&D investment increased 28% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
+20.2%
$9.6M→$11.6M

Current assets grew 20.2% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+15.5%
$11.7M→$13.5M

Asset base grew 15.5% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-11-14
PRIOR — 2025-09-12
ADDED
The December 31, 2024 , condensed consolidated balance sheet was derived from the Company s audited financial statements.
These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company s condensed consolidated financial position as of September 30, 2025 , and its results of operations, changes in temporary equity and stockholders equity (deficit) and cash flows for the nine months ended September 30, 2025 and 2024 .
The results of operations for the nine months ended September 30, 2025 , are not necessarily indicative of the results to be expected for the year ending December 31, 2025 , or for any other future annual or interim period.
The Company has incurred operating losses and negative cash flows from operations for the nine months ended September 30, 2025 , and SynCardia has a history of operating losses dating back to its inception.
For the year ended December 31, 2024 , the Company raised $ 11.8 million, net of repayments from the issuance of debt.
For the nine months ended September 30, 2025 , the Company raised $ 3.7 million, net of repayments, from the issuance of debt and $ 17.4 million of net proceeds from the issuance of common stock.
Accounts in the United States are secured by the Federal Deposit Insurance Corporation ( FDIC ) up to $250,000.
As of September 30, 2025 , the Company had no unconditional and noncancelable purchase commitments.
As of September 30, 2025 and December 31, 2024 , the Company has assessed no impairment of goodwill.
As of September 30, 2025 and December 31, 2024 , the Company has assessed no impairment of its long-lived assets.
REMOVED
Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Changes in Temporary Equity and Stockholders Deficit for the three and six months ended June 31, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 31, 2025 and 2024 4 Notes to Financial Statements (Unaudited) 5 Item 2.
Exhibits 41 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the Form 10-Q ) includes statements that are, or may be deemed to be, forward-looking statements within the meaning of the U.S.
The December 31, 2024, condensed consolidated balance sheet was derived from the Company s audited financial statements.
These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company s condensed consolidated financial position as of June 30, 2025, and its results of operations, changes in temporary equity and stockholders deficit and cash flows for the six months ended June 30, 2025 and 2024.
The results of operations for the six months ended June 30, 2025, are not necessarily indicative of the results to be expected for the year ending December 31, 2025, or for any other future annual or interim period.
The Company has incurred operating losses and negative cash flows from operations for the six months ended June 30, 2025, and SynCardia has a history of operating losses dating back to its inception.
For the year ended December 31, 2024, the Company raised $ 11.8 million, net of repayments from the issuance of debt.
For the six months ended June 30, 2025, the Company raised $ 3.7 million, net of repayments, from the issuance of debt and $ 1.5 million from the issuance of common stock.
Accounts in the United States are secured by the Federal Deposit Insurance Corporation ( FDIC ) up to $ 250,000 .
As of June 30, 2025, the Company had no unconditional and noncancelable purchase commitments.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →